BioSpace News Archive

The global transplantation market size is projected to surpass around USD 27.07 billion by 2027, growing at a CAGR of 9.5% during forecast period from 2022 to 2027.

Nihon Kohden, a U.S. market leader in precision medical products and services, announced today the launch of the Smart Cable™ NMT Pod and disposable electrode, allowing clinicians to monitor neuromuscular blockade with confidence.

ANGLE plc, a world-leading liquid biopsy company, announces that following the exercise of employee options, it has issued and allotted 25,000 new ordinary shares of £0.10 each in the Company.

Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its third quarter 2022 financial results on Friday, November 4, 2022, prior to its earnings call at 8:00 a.m. ET.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Statera Biopharma, Inc., a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced that the Company filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 with the Securities and Exchange Commission.

Novocure announced 11 poster presentations on Tumor Treating Fields will be featured at the American Society for Radiation Oncology 2022 Annual Meeting from Oct. 23 to Oct. 26 in San Antonio, Texas.

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that data from its landmark ReOpen phase 3 clinical trial program will be presented at IDWeek 2022 in Washington, D.C. today.

Matinas BioPharma announced today that Jerome D. Jabbour, Chief Executive Officer of Matinas BioPharma, will present at the ThinkEquity Investment Conference on Wednesday, October 26, 2022, at 10:30 a.m. ET, and host investor meetings.

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the third quarter of 2022 on Monday, November 7, 2022 before the opening of the U.S. financial markets.